department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Klisyri · pharmadog

pharmadog
drugs
Klisyri

drug

patient view →

tirbanibulin

Marketedupdated 2mo ago

by Almirall SA

Approved

community read0 votes

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

Klisyri

generic

tirbanibulin

indication

Actinic (Solar) Keratosis

phase

marketed

Data sources

ClinicalTrials.gov

last refreshed 30m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

Patent cliff

source: FDA Orange Book

first barrier falls

Jun 7, 2027

335 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (6)

Sep 7, 2038compositionUS 10669236
Mar 12, 2038method-of-use (U-3015)US 10617693
Mar 12, 2038method-of-use (U-3015)US 11497750
Dec 28, 2030compositionUS 73009314.5y
Feb 2, 2029compositionUS 78514702.6y
Dec 28, 2027formulationUS 103230011.5y

FDA exclusivities (1)

Jun 7, 2027D-192New Indication (3y)335d

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Trials studying tirbanibulin

phase4Tirbanibulin for Pediatric Wartsrecruitingn=10
phase3A Study to Evaluate the Efficacy and Safety of Tirbanibulin Ointment in Adult Participants With Actinic Keratosiscompletedn=280
phase3Efficacy and Safety of Cryotherapy Followed by Tirbanibulin Ointment for Actinic Keratosis on the Scalp and Foreheadnot yet recruitingn=59
phase4A Study of Tirbanibulin on the Wellbeing of Participants With Actinic Keratosescompletedn=334
phase4A Study of Tirbanibulin Ointment and Diclofenac Sodium Gel for the Treatment of Adult Participants With Actinic Keratosis on the Face or Scalpactive not recruitingn=447
—Patient and Clinician Reported Outcomes for Tirbanibulin Effectiveness and Safety in Actinic Keratosiscompletedn=300
phase4Tirbanibulin 1% Ointment for the Treatment of Actinic Keratosis on the Back of the Handswithdrawn
phase3A Study to Evaluate the Safety and Tolerability of Tirbanibulin Ointment 1% in Adult Participants With Actinic Keratosiscompletedn=105

more trials →